Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
Arrowhead Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Arrowhead Pharmaceuticals's price to sales ratio was 10.4× on Nov 11, 2026, against 8.6× a year earlier. Over the last 5 years it ranged from 4.0× to 150.7×, with a median of 14.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 10.4× | −0.5 |
| 2025 | Dec 31, 2025 | 10.9× | −110.7 |
| 2024 | Oct 31, 2024 | 121.6× | +107.9 |
| 2023 | Dec 29, 2023 | 13.6× | −4.0 |
| 2022 | Dec 30, 2022 | 17.7× | −32.3 |
| 2021 | Dec 31, 2021 | 50.0× | −39.3 |
| 2020 | Dec 31, 2020 | 89.3× | +53.4 |
| 2019 | Dec 31, 2019 | 35.9× | −32.2 |
| 2018 | Dec 31, 2018 | 68.1× | +59.3 |
| 2017 | Dec 29, 2017 | 8.8× | −428.7 |
| 2013 | Jul 31, 2013 | 437.5× | +239.6 |
| 2012 | Dec 31, 2012 | 197.8× | +75.6 |
| 2011 | Dec 30, 2011 | 122.3× | – |
See a number that looks wrong?